{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T22:05:14Z","timestamp":1772921114645,"version":"3.50.1"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,24]],"date-time":"2024-12-24T00:00:00Z","timestamp":1734998400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","nmd-journal.com","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuromuscular Disorders"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.nmd.2024.105270","type":"journal-article","created":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T22:54:15Z","timestamp":1734735255000},"page":"105270","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["The influence of genotype on the natural history of types 1 - 3 spinal muscular atrophy"],"prefix":"10.1016","volume":"47","author":[{"given":"C. Simone","family":"Sutherland","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophie","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valerie Aponte","family":"Ribero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alex","family":"Simpson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christos","family":"Kokaliaris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renata S.","family":"Scalco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carol Jean","family":"Guittari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ksenija","family":"Gorni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Darryl C.","family":"De Vivo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William B.","family":"Martens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teresa M.","family":"Karrer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.nmd.2024.105270_bib0001","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.ncl.2015.07.004","article-title":"Spinal muscular atrophy","volume":"33","author":"Kolb","year":"2015","journal-title":"Neurol Clin"},{"key":"10.1016\/j.nmd.2024.105270_bib0002","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1038\/s41572-022-00380-8","article-title":"Spinal muscular atrophy","volume":"8","author":"Mercuri","year":"2022","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.nmd.2024.105270_bib0003","doi-asserted-by":"crossref","first-page":"870","DOI":"10.3346\/jkms.2004.19.6.870","article-title":"Quantitative analysis of SMN1 gene and estimation of SMN1 deletion carrier frequency in Korean population based on real-time PCR","volume":"19","author":"Lee","year":"2004","journal-title":"J Korean Med Sci"},{"key":"10.1016\/j.nmd.2024.105270_bib0004","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.ajhg.2009.08.002","article-title":"A positive modifier of spinal muscular atrophy in the SMN2 gene","volume":"85","author":"Prior","year":"2009","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.nmd.2024.105270_bib0005","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/1750-1172-6-71","article-title":"Spinal muscular atrophy","volume":"6","author":"D'Amico","year":"2011","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.nmd.2024.105270_bib0006","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1146\/annurev-genom-102319-103602","article-title":"Twenty-five years of spinal muscular atrophy research: from phenotype to genotype to therapy, and what comes next","volume":"21","author":"Wirth","year":"2020","journal-title":"Annu Rev Genomics Hum Genet"},{"key":"10.1016\/j.nmd.2024.105270_bib0007","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1002\/cpt.2247","article-title":"Prognostic factors and treatment-effect modifiers in spinal muscular atrophy","volume":"110","author":"Baranello","year":"2021","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.nmd.2024.105270_bib0008","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1002\/(SICI)1098-1004(200003)15:3<228::AID-HUMU3>3.0.CO;2-9","article-title":"An update of the mutation spectrum of the survival motor neuron gene (SMN1) in autosomal recessive spinal muscular atrophy (SMA)","volume":"15","author":"Wirth","year":"2000","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.nmd.2024.105270_bib0009","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.2147\/DDDT.S214174","article-title":"Disease modifying therapies for the management of children with spinal muscular atrophy (5q SMA): an update on the emerging evidence","volume":"16","author":"Hjartarson","year":"2022","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.nmd.2024.105270_bib0010","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.nmd.2018.01.003","article-title":"Correlation between SMA type and SMN2 copy number revisited: an analysis of 625 unrelated Spanish patients and a compilation of 2834 reported cases","volume":"28","author":"Calucho","year":"2018","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nmd.2024.105270_bib0011","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/gt.2017.52","article-title":"The clinical landscape for SMA in a new therapeutic era","volume":"24","author":"Talbot","year":"2017","journal-title":"Gene Ther"},{"key":"10.1016\/j.nmd.2024.105270_bib0012","doi-asserted-by":"crossref","first-page":"e1634","DOI":"10.1212\/WNL.0000000000009248","article-title":"Population-based analysis of survival in spinal muscular atrophy","volume":"94","author":"Wijngaarde","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2024.105270_bib0013","article-title":"Spinal muscular atrophy: from approved therapies to future therapeutic targets for personalized medicine","volume":"2","author":"Chaytow","year":"2021","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.nmd.2024.105270_bib0014","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.2147\/TCRM.S172291","article-title":"Clinical evidence supporting early treatment of patients with spinal muscular atrophy: current perspectives","volume":"15","author":"Dangouloff","year":"2019","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.nmd.2024.105270_bib0015","unstructured":"ClinicalTrials.gov. NCT03779334: a study of risdiplam in infants with genetically diagnosed and presymptomatic spinal muscular atrophy (RAINBOWFISH). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03779334?term=RAINBOWFISH&rank=1. 2024;2024 [accessed November 2024]."},{"key":"10.1016\/j.nmd.2024.105270_bib0016","unstructured":"ClinicalTrials.gov. NCT02386553: a study of multiple doses of ISIS SMNRx (ISIS 396443) delivered to infants with genetically diagnosed and presymptomatic spinal muscular atrophy (NURTURE). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02386553. 2024; [accessed July 2023]."},{"key":"10.1016\/j.nmd.2024.105270_bib0017","unstructured":"ClinicalTrials.gov. NCT03505099: pre-symptomatic study of intravenous AVXS-101 in Spinal muscular atrophy (SMA) for patients with multiple copies of SMN2 (SPR1NT). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03505099?term=AVXS-101+presymptomatic&rank=1. 2022; [accessed July 2023]."},{"key":"10.1016\/j.nmd.2024.105270_bib0018","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.nmd.2017.05.011","article-title":"Spinal muscular atrophy: a changing phenotype beyond the clinical trials","volume":"27","author":"Tizzano","year":"2017","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nmd.2024.105270_bib0019","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.ejpn.2024.06.001","article-title":"2024 update: european consensus statement on gene therapy for spinal muscular atrophy","volume":"51","author":"Kirschner","year":"2024","journal-title":"Eur J Paediatr Neurol"},{"key":"10.1016\/j.nmd.2024.105270_bib0020","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1016\/j.nmd.2021.07.008","article-title":"Newborn screening of neuromuscular diseases","volume":"31","author":"Dangouloff","year":"2021","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nmd.2024.105270_bib0021","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/s13023-021-01771-y","article-title":"Observation of the natural course of type 3 spinal muscular atrophy: data from the polish registry of spinal muscular atrophy","volume":"16","author":"Lusakowska","year":"2021","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.nmd.2024.105270_bib0022","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1212\/WNL.0000000000000741","article-title":"Observational study of spinal muscular atrophy type I and implications for clinical trials","volume":"83","author":"Finkel","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2024.105270_bib0023","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1136\/jnnp-2016-314292","article-title":"Association of motor milestones, SMN2 copy and outcome in spinal muscular atrophy types 0-4","volume":"88","author":"Wadman","year":"2017","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.nmd.2024.105270_bib0024","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0202104","article-title":"Spinal muscular atrophy within Amish and Mennonite populations: ancestral haplotypes and natural history","volume":"13","author":"Carson","year":"2018","journal-title":"PLoS ONE"},{"key":"10.1016\/j.nmd.2024.105270_bib0025","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1002\/ana.25101","article-title":"Natural history of infantile-onset spinal muscular atrophy","volume":"82","author":"Kolb","year":"2017","journal-title":"Ann Neurol"},{"key":"10.1016\/j.nmd.2024.105270_bib0026","unstructured":"SMA Foundation. Research: clinical research. https:\/\/smafoundation.org\/research\/clinical\/. 2023; [accessed February 2022]."},{"key":"10.1016\/j.nmd.2024.105270_bib0027","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1212\/WNL.0b013e318271f7e4","article-title":"Prospective cohort study of spinal muscular atrophy types 2 and 3","volume":"79","author":"Kaufmann","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2024.105270_bib0028","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1212\/WNL.0000000000002445","article-title":"Results from a Phase 1 study of nusinersen (ISIS-SMNRx) in children with spinal muscular atrophy","volume":"86","author":"Chiriboga","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2024.105270_bib0029","unstructured":"Therneau T. Package 'Survival'. https:\/\/cran.r-project.org\/web\/packages\/survival\/survival.pdf. 2024; [accessed July 2023]."},{"key":"10.1016\/j.nmd.2024.105270_bib0030","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1186\/s12887-022-03671-x","article-title":"Advances and limitations for the treatment of spinal muscular atrophy","volume":"22","author":"Day","year":"2022","journal-title":"BMC Pediatr"},{"key":"10.1016\/j.nmd.2024.105270_bib0031","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3233\/JND-190424","article-title":"Advances in treatment of spinal muscular atrophy - new phenotypes, new challenges, new implications for care","volume":"7","author":"Schorling","year":"2020","journal-title":"J Neuromuscul Dis"},{"key":"10.1016\/j.nmd.2024.105270_bib0032","doi-asserted-by":"crossref","first-page":"2935","DOI":"10.1007\/s00431-023-04883-8","article-title":"New therapies for spinal muscular atrophy: where we stand and what is next","volume":"182","author":"Antonaci","year":"2023","journal-title":"Eur J Pediatr"},{"key":"10.1016\/j.nmd.2024.105270_bib0033","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1186\/s13023-022-02455-x","article-title":"Natural history of Type 1 spinal muscular atrophy: a retrospective, global, multicenter study","volume":"17","author":"Cances","year":"2022","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.nmd.2024.105270_bib0034","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.braindev.2020.07.012","article-title":"Natural history in spinal muscular atrophy Type I in Taiwanese population: a longitudinal study","volume":"43","author":"Ou","year":"2021","journal-title":"Brain Dev"},{"key":"10.1016\/j.nmd.2024.105270_bib0035","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.braindev.2017.04.018","article-title":"Relationships between long-term observations of motor milestones and genotype analysis results in childhood-onset Japanese spinal muscular atrophy patients","volume":"39","author":"Kaneko","year":"2017","journal-title":"Brain Dev"},{"key":"10.1016\/j.nmd.2024.105270_bib0036","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0022-510X(96)00284-5","article-title":"Hausmanowa-Petrusewicz I. A collaborative study on the natural history of childhood and juvenile onset proximal spinal muscular atrophy (type II and III SMA): 569 patients","volume":"146","author":"Zerres","year":"1997","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.nmd.2024.105270_bib0037","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1212\/WNL.47.4.973","article-title":"Function changes in spinal muscular atrophy II and III. The DCN\/SMA Group","volume":"47","author":"Russman","year":"1996","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2024.105270_bib0038","doi-asserted-by":"crossref","first-page":"e548","DOI":"10.1542\/peds.2004-0668","article-title":"Spinal muscular atrophy: survival pattern and functional status","volume":"114","author":"Chung","year":"2004","journal-title":"Pediatrics"},{"key":"10.1016\/j.nmd.2024.105270_bib0039","doi-asserted-by":"crossref","first-page":"e2103","DOI":"10.1212\/WNL.0000000000207878","article-title":"Systematic literature review of the natural history of spinal muscular atrophy: motor function, scoliosis, and contractures","volume":"101","author":"Aponte Ribero","year":"2023","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2024.105270_bib0040","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0139950","article-title":"Biomarker for spinal muscular atrophy: expression of SMN in peripheral blood of SMA patients and healthy controls","volume":"10","author":"Czech","year":"2015","journal-title":"PLoS ONE"},{"key":"10.1016\/j.nmd.2024.105270_bib0041","doi-asserted-by":"crossref","first-page":"e33572","DOI":"10.1371\/journal.pone.0033572","article-title":"Evaluation of SMN protein, transcript, and copy number in the biomarkers for spinal muscular atrophy (BforSMA) clinical study","volume":"7","author":"Crawford","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.nmd.2024.105270_bib0042","doi-asserted-by":"crossref","first-page":"859","DOI":"10.2298\/VSP140328072Z","article-title":"Association between the SMN2 gene copy number and clinical characteristics of patients with spinal muscular atrophy with homozygous deletion of exon 7 of the SMN1 gene","volume":"72","author":"Zarkov","year":"2015","journal-title":"Vojnosanit Pregl"},{"key":"10.1016\/j.nmd.2024.105270_bib0043","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.nmd.2021.01.012","article-title":"Understanding European patient expectations towards current therapeutic development in spinal muscular atrophy","volume":"31","author":"Gusset","year":"2021","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nmd.2024.105270_bib0044","doi-asserted-by":"crossref","first-page":"109","DOI":"10.3233\/JND-200475","article-title":"Infants diagnosed with spinal muscular atrophy and 4 SMN2 copies through newborn screening - opportunity or burden?","volume":"7","author":"Muller-Felber","year":"2020","journal-title":"J Neuromuscul Dis"},{"key":"10.1016\/j.nmd.2024.105270_bib0045","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1136\/jmg-2022-108873","article-title":"Experience of a 2-year spinal muscular atrophy NBS pilot study in Italy: towards specific guidelines and standard operating procedures for the molecular diagnosis","volume":"60","author":"Abiusi","year":"2023","journal-title":"J Med Genet"},{"key":"10.1016\/j.nmd.2024.105270_bib0046","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.nmd.2021.03.007","article-title":"Newborn screening programs for spinal muscular atrophy worldwide: where we stand and where to go","volume":"31","author":"Dangouloff","year":"2021","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nmd.2024.105270_bib0047","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1017\/cjn.2020.229","article-title":"Newborn screening for spinal muscular atrophy: ontario testing and follow-up recommendations","volume":"48","author":"McMillan","year":"2021","journal-title":"Can J Neurol Sci"},{"key":"10.1016\/j.nmd.2024.105270_bib0048","unstructured":"Hern\u00e1n M., Pinilla P., Thorlund K., Kent S. Quantifying bias in real-world studies: a new hope for RWD acceptance or are HTAers gonna hate? Presented at ISPOR europe 2022. https:\/\/www.ispor.org\/docs\/default-source\/euro2022\/ispor-ad-symposium-combined-slides-final-v4.pdf?sfvrsn=9e41ba3-0.2022 [accessed May 2024]."},{"key":"10.1016\/j.nmd.2024.105270_bib0049","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1177\/0883073807305788","article-title":"Consensus statement for standard of care in spinal muscular atrophy","volume":"22","author":"Wang","year":"2007","journal-title":"J Child Neurol"},{"key":"10.1016\/j.nmd.2024.105270_bib0050","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.nmd.2017.11.005","article-title":"Diagnosis and management of spinal muscular atrophy: part 1: recommendations for diagnosis, rehabilitation, orthopedic and nutritional care","volume":"28","author":"Mercuri","year":"2018","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nmd.2024.105270_bib0051","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.nmd.2017.11.004","article-title":"Diagnosis and management of spinal muscular atrophy: part 2: pulmonary and acute care; medications, supplements and immunizations; other organ systems; and ethics","volume":"28","author":"Finkel","year":"2018","journal-title":"Neuromuscul Disord"}],"container-title":["Neuromuscular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896624017668?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896624017668?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T12:26:35Z","timestamp":1741695995000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960896624017668"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":51,"alternative-id":["S0960896624017668"],"URL":"https:\/\/doi.org\/10.1016\/j.nmd.2024.105270","relation":{},"ISSN":["0960-8966"],"issn-type":[{"value":"0960-8966","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The influence of genotype on the natural history of types 1 - 3 spinal muscular atrophy","name":"articletitle","label":"Article Title"},{"value":"Neuromuscular Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nmd.2024.105270","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"105270"}}